Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

Novartis drug Pelacarsen that targets Lp(a) cholesterol is in global phase 3 trials. Last year, the company launched ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

The focus is on a drug called Lepodisiran, that could target certain factors that increase risk of heart attacks and strokes.

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

The U.S. Food and Drug Administration is replacing animal testing with human-relevant methods, including artificial ...

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

A new drug called lepodisiran may offer hope to millions of people at risk of heart attacks and strokes by targeting a little ...

Genetically modified mosquitoes have been released in the United States, taking flight in Florida. They are intended to ...